ATX-MS-1467
ATX-MS-1467 is a potential new treatment for people with relapsing remitting multiple sclerosis (MS).
Other names:
In development for: Relapsing remitting MS
Status: Phase I
Last updated: March 2011
How does it work?
Some of the damage to nerves in MS may be caused by T-cells (a type of white blood cell or lymphocyte) which mistakenly identify the myelin coating of nerves as 'foreign'. Myelin basic protein (MBP) is believed to be an important component in the myelination of nerves in the brain and spinal cord. ATX-MS-1467 consists of four short peptides (chains of amino acids, the building blocks of proteins) derived from MBP. ATX-MS-1467 is intended to selectively inhibit the immune system's harmful attack on the nerve coating by reducing T-cell response to myelin.
How is it given?
ATX-MS-1467 is injected under the skin (either intra-dermally or subcutaneously) once every two weeks.
Clinical studies
In a phase I/IIa study, 6 people with secondary progressive MS received increasing doses 7 to 14 days apart. The results showed a reduction in the T-cell response to myelin basic protein and the treatment was found to be safe and well tolerated in this small group of people. The study was not designed to provide data on clinical efficacy.
Further clinical trials
-
Phase I study
A phase I study is currently underway to evaluate ATX-MS-1467 in 40 people with relapsing remitting MS and is recruiting in the UK. Study centres include Stoke on Trent, Sheffield, Nottingham, Oxford, London and Plymouth. More information about recruitment for this trial.
Side effects and contraindications
No adverse effects have been reported from the phase I clinical trial.